Please login to the form below

Not currently logged in
Email:
Password:

semaglutide

This page shows the latest semaglutide news and features for those working in and with pharma, biotech and healthcare.

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

with some compelling data from a series of head-to-head trials of it next-generation treatment semaglutide. ... Victoza. Oral semaglutide also outperformed Boehringer Ingelheim and Lilly’s Jardiance pill in the head-to-head PIONEER 2 study.

Latest news

  • The year of the blockbuster The year of the blockbuster

    Ozempic (semaglutide) from Novo Nordisk:Novo’s weekly GLP1 analogue was approved for use in patients with type 2 diabetes late last year and launched in February 2018.

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    Novo’ s diabetes pill defeats Merck’ s Januvia in trial. Oral semaglutide also outshines its best-selling diabetes injectable Victoza. ... A familiar story was told when oral semaglutide was compared with Novo’s best-selling diabetes blockbuster

  • Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1 Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

    Novo claimed approval for its own once-weekly GLP-1 drug – Ozempic (semaglutide) – towards the end of last year, and the new product made DKK 69m in its first few weeks ... to Trulicity, and is also making progress to filing its oral formulation of

  • Novo Nordisk’s semaglutide obesity trial hits the mark Novo Nordisk’s semaglutide obesity trial hits the mark

    Novo Nordisk’ s semaglutide obesity trial hits the mark. The injection helped adults lose up to 13.8% of their body weight in a year. ... Two thirds (65%) of subjects on semaglutide experienced weight loss of 10% or more, compared to 10% with placebo

  • Novo's oral semaglutide ‘safe and well-tolerated’ Novo's oral semaglutide ‘safe and well-tolerated’

    Novo's oral semaglutide ‘ safe and well-tolerated’. Releases first phase III data on the new version of its diabetes treatment. ... The trial achieved its primary objective by demonstrating significant and superior improvements in long-term blood

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Development. Semaglutide once weekly, ZP Patch Technology. 115. Andromeda / Teva Pharmaceutical Industries.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics